Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "COVID 19 - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
The report provides a detailed examination of over 100 companies and 110 drugs in the COVID-19 competitive landscape. The report evaluates therapeutics by product type, stage, route of administration, and molecule type, while also noting inactive pipeline products. The geographical outreach of this analysis is global.
COVID-19, caused by the novel coronavirus SARS-CoV-2, presents a range of symptoms from mild to severe illness and poses complications such as pneumonia and respiratory failure. Prevention efforts emphasize vaccination, hygiene, and social distancing.
Company and Product Profiles
Roche, a leader in biotechnology and diagnostics, has played a pivotal role in fighting COVID-19 with diagnostics and support solutions. Their product, Actemra, has been used under emergency conditions to manage severe COVID-19 cases.
Bharat Biotech, renowned for over 145 global patents, has contributed significantly with BBV154, a nasal vaccine developed in partnership with Washington University. It represents a cost-effective solution for low to middle-income countries.
Bioxytran's ProLectin-M is an oral drug aiming to inhibit SARS-CoV-2 entry into cells. Possessing promising trial results, it is preparing for Phase III trials.
Enanta Pharmaceuticals is progressing with EDP-235, a potent antiviral targeting COVID-19, currently in Phase II clinical development.
Sinovac Biotech is advancing SA55, a neutralizing antibody candidate approved for clinical trials, to bolster prevention strategies.
Immorna and Immunome are forging forward with innovative RNA and antibody-based therapeutics, illustrating the wide array of treatment modalities under development.
Collaborative Efforts and Emerging Questions
The report delves into a myriad of collaborations comprising licensing and acquisitions, thus spotlighting the industry's dynamic partnerships. Key questions addressed in the report include the number of active and emerging drugs, collaborations, and the status of clinical trials.
COVID-19 Competitive Landscape
An analytical view of the competitive landscape includes insights into the current treatment scenario, unmet needs, and the emergence of novel therapies. The report examines the potential of emerging drugs in development stages and spotlights industry-academia collaborations.
Overall, this report serves as a cornerstone for understanding the evolution of COVID-19 therapies and the competitive dynamics shaping the market landscape through 2026.
Key Developments in COVID-19 Treatments
- July 2025: A rare drug trial for long COVID failed, offering insights into study design for subsequent trials.
- May 2025: A novel messenger RNA vaccine targeting both COVID-19 and seasonal flu showed impressive results in a Phase III trial, bolstering Moderna's portfolio.
- January 2025: Humanetics Corporation revealed positive Phase II results for BIO 300, aimed at improving lung function post-COVID.
Companies Featured
- Bioxytran Inc
- Enanta Pharmaceuticals
- Sinovac Biotech
- Immorna
- Immunome, Inc
- Aligos Therapeutics
- Neutrolis Therapeutics
- Corat Therapeutics
- Capricor
- Frontier Biotechnologies
- Synairgen
- Incyte Corporation/Novartis
- Atea Pharmaceuticals
- Fulcrum Therapeutics
- Evgen Pharma
- Karyopharm Therapeutics
- Turn Therapeutics
- MetrioPharm
- Akari Therapeutics
- CervoMed
- AIM ImmunoTech
- Oncovir
- Midwestern University/Pharmazz
- Deverra Therapeutics
- Apros Therapeutics
- Viravaxx
- Ark Biosciences
- Invivyd
- Sareum
- Haya Therapeutics
- Iontas
For more information about this report visit https://www.researchandmarkets.com/r/o3bs8s
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
